Skip to main content
. 2026 Feb 11;18(4):595. doi: 10.3390/cancers18040595
ADT Androgen deprivation therapy
CSS Cancer-specific survival
EBRT External beam radiotherapy
HDR-BT High-dose-rate brachytherapy
HT Hormonal therapy
NCCN National Comprehensive Cancer Network
OS Overall survival
PC Prostate cancer
PSA Prostate-specific antigen
PSMA-PET Prostate-specific membrane antigen positron emission tomography
RFS Recurrence-free survival
RP Radical prostatectomy
RT Radiotherapy
SBRT Stereotactic body radiotherapy
VHR Very high-risk